The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells
Open accessAbstract
Abstract —Migration of vascular smooth muscle cells (VSMCs) plays an important role in atherogenesis and restenosis after arterial interventions. The expression of matrix metalloproteinases (MMPs), particularly MMP-9, contributes to VSMC migration. This process requires degradation of basal laminae and other components of the arterial extracellular matrix. Peroxisome proliferator-activated receptors (PPARs), members of the nuclear receptor family, regulate gene expression after activation by various ligands. Recent studies have suggested opposing effects of PPAR gamma (PPARγ) activation on atherogenesis. The present study tested the hypotheses that human VSMCs express PPAR alpha (PPARα) and PPARγ and that PPAR agonists in VSMCs modulate MMP-9 expression and activity, as well as VSMC migration. Human VSMCs expressed PPARα and PPARγ mRNA and protein. Treatment of VSMCs with the PPARγ ligands troglitazone and the naturally occurring 15-deoxy- Δ12,14 -prostaglandin J 2 (15d-PGJ 2 ) decreased phorbol 12-myristate 13-acetate–induced MMP-9 mRNA and protein levels, as well as MMP-9 gelatinolytic activity in the supernatants in a concentration-dependent manner. Six different PPARα activators lacked such effects. Addition of prostaglandin F 2α , known to limit PPARγ activity, diminished the MMP-9 inhibition seen with either troglitazone or 15d-PGJ 2 , further implicating PPARγ in these effects. Finally, troglitazone and 15d-PGJ 2 inhibited the platelet-derived growth factor-BB–induced migration of VSMCs in vitro in a concentration-dependent manner. PPARγ activation may regulate VSMC migration and expression and activity of MMP-9. Thus, PPARγ activation in VSMCs, via the antidiabetic agent troglitazone or naturally occurring ligands, may act to counterbalance other potentially proatherosclerotic PPARγ effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Galis, Z. S., Sukhova, G. K., Lark, M. W., & Libby, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117619 · Cited by 2,539
Self-citationKliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,860
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Clowes, A. W., Reidy, M. A., & Clowes, M. M. (1983) · PubMed · Cited by 1,437
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene
Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A.-M., Saladin, R., Najib, J., Laville, M., Fruchart, J.-C., Deeb, S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18779 · Cited by 1,188
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I. P., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J.-C., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., & Wahli, W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2160 · Cited by 948
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W., & Glass, C. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7614 · Cited by 721
Zhu, Y., Qi, C., Korenberg, J. R., Chen, X. N., Noya, D., Rao, M. S., & Reddy, J. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7921 · Cited by 653
Galis, Z. S., Muszynski, M., Sukhova, G. K., Simon-Morrissey, E., Unemori, E. N., Lark, M. W., Amento, E., & Libby, P. (1994) · Circulation Research · doi:10.1161/01.res.75.1.181 · Cited by 646
Self-citationBendeck, M. P., Zempo, N., Clowes, A. W., Galardy, R. E., & Reidy, M. A. (1994) · Circulation Research · doi:10.1161/01.res.75.3.539 · Cited by 584
Macrophages in Human Atheroma Contain PPARγ
Marx, N., Sukhova, G., Murphy, C., Libby, P., & Plutzky, J. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65540-x · Cited by 529
Self-citationPeroxisome proliterator-activated receptors, orphans with ligands and functions
Schoonjans, K., Martin, G., Staels, B., & Auwerx, J. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 489
Brown, D. L., Hibbs, M. S., Kearney, M., Loushin, C., & Isner, J. M. (1995) · Circulation · doi:10.1161/01.cir.91.8.2125 · Cited by 487
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118991 · Cited by 476
Nuclear Receptor/AP-1 Interaction*
PFAHL, M. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-5-651 · Cited by 446
Schönbeck, U., Mach, F., Sukhova, G. K., Murphy, C., Bonnefoy, J.-Y., Fabunmi, R. P., & Libby, P. (1997) · Circulation Research · doi:10.1161/01.res.81.3.448 · Cited by 334
Self-citationEffect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus
Schwartz, S., Raskin, P., Fonseca, V., & Graveline, J. F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381302 · Cited by 331
Retinoic Acid Blocks Adipogenesis by Inhibiting C/EBPβ-Mediated Transcription
Schwarz, E. J., Reginato, M. J., Shao, D., Krakow, S. L., & Lazar, M. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1552 · Cited by 302
Self-citationReginato, M. J., Krakow, S. L., Bailey, S. T., & Lazar, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.1855 · Cited by 277
Self-citationFABUNMI, R. P., BAKER, A. H., MURRAY, E. J., BOOTH, R. F. G., & NEWBY, A. C. (1996) · Biochemical Journal · doi:10.1042/bj3150335 · Cited by 251
Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J. C., Auwerx, J., & Staels, B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47383-8 · Cited by 243
Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients
Cominacini, L., Garbin, U., Pasini, A. F., Campagnola, M., Davoli, A., FOOT, E. A., Sighieri, G., Sironi, A. M., Cascio, V. L., & Ferrannini, E. (1998) · Diabetes · doi:10.2337/diab.47.1.130 · Cited by 105
Negative and Positive Transcriptional Regulation by Thyroid Hormone Receptor Isoforms
Rentoumis, A., Krishna, V., Chatterjee, K., Madison, L. D., Datta, S., Gallagher, G. D., DeGroot, L. J., & Jameson, J. L. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-10-1522 · Cited by 69
Another Potential Use of Troglitazone in Noninsulin-Dependent Diabetes Mellitus
Minamikawa, J., Yamauchi, M., Inoue, D., & Koshiyama, H. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.1041 · Cited by 44
Cited by
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Metadata
- Authors
- Marx, N., Schönbeck, U., Lazar, M. A., Libby, P., & Plutzky, J.
- Venue
- Circulation Research
- Published
- 1998-11-30
- Volume
- 83
- Issue
- 11
- Pages
- 1097-1103
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2168332555
- Cited by
- 587
- References
- 34
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.